[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-disease-end-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-disease-end-stage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,81,109,146,170,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100645075","comparison-of-the-effects-of-general-anesthesia-and-combined-spinal-epidural-anesthesia-on-ferroptosis-humanin-and-mots-c-levels-in-renal-transplantation-100645075",false,"NCT07678073","COMPARISON OF THE EFFECTS OF GENERAL ANESTHESIA AND COMBINED SPINAL-EPIDURAL ANESTHESIA ON FERROPTOSIS, HUMANIN, AND MOTS-C LEVELS IN RENAL TRANSPLANTATION","COMPARISON OF THE EFFECTS OF GENERAL ANESTHESIA AND COMBINED SPINAL-EPIDURAL ANESTHESIA ON FERROPTOSIS, HUMANIN, AND MOTS-C LEVELS IN RENAL TRANSPLANTATION: A PROSPECTIVE CONTROLLED STUDY","Inclusion Criteria:\n\n* Patients aged 18-70 years with American Society of Anesthesiologists (ASA) physical status I-III.\n* Patients scheduled for elective living-donor allogeneic kidney transplantation.\n* Patients receiving sevoflurane-based general anesthesia as the anesthetic technique.\n* Patients receiving combined spinal-epidural anesthesia as the anesthetic technique.\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 70 years.\n* Patients undergoing deceased-donor kidney transplantation.\n* Patients receiving total intravenous anesthesia (TIVA).\n* Patients who decline to participate in the study or are unable to provide informed consent.\n* Patients with American Society of Anesthesiologists (ASA) physical status IV or V.\n* Patients with a history of previous organ transplantation.\n* Patients with known or suspected mitochondrial disorders.\n* Patients with a history of chronic corticosteroid use.\n* Patients requiring red blood cell transfusion intraoperatively or within the first 24 postoperative hours.\n* Patients with a primary warm ischemia time \\>5 minutes, secondary warm ischemia time \\>30 minutes, or cold ischemia time \\>60 minutes.","ALL","18 Years","70 Years",{"count":20,"type":21},68,"ESTIMATED","INTERVENTIONAL",[24],"NA","Renal transplantation is the most effective renal replacement therapy for patients with end-stage renal disease. Ischemia-reperfusion injury may adversely affect graft function and long-term outcomes. Ferroptosis has recently emerged as a potential mechanism involved in ischemia-reperfusion injury, while the mitochondrial-derived peptides humanin and MOTS-c are thought to exert protective effects against oxidative stress. However, the effects of different anesthetic techniques on these biomarkers in kidney transplant recipients have not been investigated.\n\nThis prospective controlled study aims to compare the effects of sevoflurane general anesthesia (SGA) and combined spinal-epidural anesthesia (CSEA) on serum ferroptosis markers, humanin, and MOTS-c levels in adult kidney transplant recipients. Blood samples will be obtained perioperatively for biomarker analysis.\n\nThe primary objective of the study is to evaluate the effects of the anesthetic technique on serum ferroptosis markers, humanin, and MOTS-c levels. Secondary objectives include evaluating early graft function and postoperative outcomes by assessing the incidence of delayed graft function, postoperative serum creatinine levels, requirement for dialysis, urine output, length of hospital stay, and the association of these outcomes with perioperative biomarker levels.",[27,28,29,30,31],"Kidney Disease, End-Stage","Kidney Transplant","Kidney","Kidney Disease","Renal Transplant",[33,34,35,36,37,38,39,40,41],"GENERAL ANESTHESIA","REGIONAL ANESTHESIA","KIDNEY TRANSPLANTATION","CELLULAR STRESS RESPONSE","CELLULAR STRESS","ANESTHESIA","HUMANIN","MOTS-c","FERROPTOSIS","RECRUITING","2026-06-24",{"date":45,"type":46},"2026-07-01","ACTUAL",{"date":48,"type":46},"2026-03-01",{"date":50,"type":21},"2026-10-15",{"name":52,"class":53},"University of Gaziantep","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":54},"100609665","rutgers-university-study-of-the-genetics-of-kidney-disease-100609665","NCT07217535","Rutgers University Study of the Genetics of Kidney Disease","The Rutgers University Study of the Genetics of Kidney Disease","rugcc-kd","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* able to understand and follow written instructions in English\n* have access to the internet and a computer, laptop, tablet or smart phone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home\n* willing to complete a survey with questions about health related to the study of kidney disease\n\nExclusion Criteria:\n\n* Not able to meet or fulfill any of the inclusion criter",true,{"count":65,"type":21},50000,"OBSERVATIONAL","The goal of this observational study is to learn more about how genes impact the risk of kidney disease. Anyone 18 or older living in the US is eligible, and a diagnosis of kidney disease is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.",[30,69,27,70,71,72],"Kidney Disease, Chronic","Kidney Diseases","Kidney Diseases, Chronic","Kidney Diseases,Cystic","2026-04-23",{"date":75,"type":46},"2026-04-24",{"date":73,"type":46},{"date":78,"type":21},"2028-10-31",{"name":80,"class":53},"Rutgers, The State University of New Jersey",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100411237","post-market-surveillance-study-of-the-bd-wavelinq-endoavf-system-100411237","NCT04634916","Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System","A Prospective, Multi-Center Clinical Study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis","CONNECT-AV","Inclusion Criteria:\n\n1. Subject must be either male or non-pregnant female ≥ 18 years of age with an expected lifespan sufficient to allow for completion of all study procedures.\n2. Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.\n3. Subject must be willing to comply with the protocol requirements, including clinical follow-up.\n4. Subjects who have established, non-reversible kidney failure, who are currently on dialysis at screening or are in immediate need (within 6 months of endoAVF creation) of dialysis.\n5. Target treatment vein diameter(s) for endoAVF creation ≥ 2.0 mm as measured via Duplex Ultrasound (DUS) or Venography.\n6. Target treatment artery diameter ≥ 2.0 mm as measured via Duplex Ultrasound (DUS) or Arteriogram.\n7. Subject has adequate collateral circulation to the hand, in the opinion of the Investigator.\n8. At least one superficial outflow vein diameter ≥ 2.5 mm and in communication with the target creation site via a proximal forearm perforating vein.\n\nExclusion Criteria:\n\n1. The subject is in a hypercoagulable state.\n2. The subject has known bleeding diathesis.\n3. The subject has insufficient cardiac output to support a native fistula in the opinion of the Investigator.\n4. Known history of active intravenous drug abuse.\n5. \"Planned\" major surgical procedure within 6 months following index procedure or major surgery within 30 days prior to index procedure.\n6. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.\n7. The subject has known adverse effects to sedation and\u002For anesthesia which cannot be adequately pre-medicated.\n8. Evidence of active infection on the day of the index procedure (temperature of ≥ 38.0° Celsius and\u002F or WBC of ≥ 12,000 cells\u002F μL, if collected).\n9. The subject has another medical condition, which, in the opinion of the Investigator, may cause him\u002Fher to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.\n10. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.\n11. The subject has central venous stenosis or central vein narrowing \\> 50% based on imaging on the same side as the planned endoAVF creation.\n12. Absence of a proximal forearm perforating vein feeding the target cannulation vein(s) from the target creation site via Duplex Ultrasound (DUS) or Venography.\n13. Occlusion or stenosis \\> 50% of target cannulation vein(s) such as cephalic, median cubital, basilic, etc. assessed via Duplex Ultrasound (DUS) or Venography.\n14. Significantly compromised venous or arterial flow in the treatment arm as determined by Investigator and Duplex Ultrasound (DUS) or Venography.\n15. Presence of significant calcification at the target endoAVF location that could potentially impact the effectiveness of endoAVF creation as determined by the Investigator.",{"count":90,"type":21},280,[24],"A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.",[27,94,95],"End-stage Renal Disease","Arteriovenous Fistula",[97],"EndoAVF","2026-03-25",{"date":100,"type":46},"2026-03-27",{"date":102,"type":46},"2021-03-26",{"date":104,"type":21},"2027-09",{"name":106,"class":107},"C. R. Bard","INDUSTRY",17,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":144,"locationsCount":54},"100624031","phase-4-low-dose-apixaban-added-to-standard-heparin-lock-versus-heparin-lock-alone-to-prevent-tunneled-hemodialysis-catheters-dysfunction-apicath-hd-100624031","NCT07404345","Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)","Efficacy of Low-Dose Apixaban Added to Standard Heparin Lock to Prevent Dysfunction of Tunneled Hemodialysis Catheters: A Randomized, PROBE, Parallel-Grupo Trial.","APICATH-HD","Inclusion Criteria:\n\n* Age ≥18 years with end-stage kidney disease (CKD stage 5) receiving maintenance hemodialysis or initiating hemodialysis.\n* Recently placed tunneled, double-lumen central venous hemodialysis catheter (tunneled CVC) in place for ≥8 days, with a post-placement radiograph confirming adequate tip position.\n* Permitted catheter insertion sites: right internal jugular, left internal jugular, right femoral, or left femoral vein.\n* Adequate initial catheter function, defined as ability to achieve the prescribed extracorporeal blood flow (suggested ≥300 mL\u002Fmin) for ≥8 days after catheter placement.\n* Conventional in-center hemodialysis schedule (2-3 sessions\u002Fweek) at the study unit, with expected ability to complete follow-up for up to 24 months.\n* Written informed consent provided.\n* Willingness to receive only the protocol-assigned antithrombotic prophylaxis and to avoid non-study systemic anticoagulants or antiplatelet agents during the study period.\n\nExclusion Criteria:\n\n* Non-tunneled hemodialysis catheter, subclavian catheter, or intracaval catheter placement not consistent with the protocol (e.g., catheter located in the SVC\u002FIVC without a subcutaneous tunnel, or catheter location\u002Fsite not permitted by the study).\n* Tunneled catheter placed \\\u003C8 days before randomization or radiographically confirmed catheter tip malposition at screening.\n* Active bleeding; active peptic ulcer disease; or clinically significant gastrointestinal bleeding within the past 30 days; uncorrectable INR \\>1.5; platelet count \\\u003C100,000\u002FµL.\n* High bleeding risk (HAS-BLED score \\>3) or major bleeding that is active or recent.\n* Known coagulopathy; history of heparin-induced thrombocytopenia (HIT); or allergy\u002Fhypersensitivity to heparin, citrate, or rt-PA (alteplase).\n* Severe hepatic impairment (e.g., Child-Pugh class C), clinically significant liver dysfunction that contraindicates DOAC therapy, or ongoing hemodialysis with regional citrate anticoagulation that cannot be modified per protocol.\n* Active catheter exit-site infection or bloodstream infection\u002Fbacteremia at the time of randomization.\n* Concomitant use of other systemic anticoagulants (e.g., warfarin, low-molecular-weight heparin, other DOACs) or high-intensity antiplatelet therapy (e.g., dual antiplatelet therapy).\n* Pregnancy or breastfeeding.\n* Women of childbearing potential who are unwilling to use a highly effective contraception method during the study and for 48 hours after the last dose of study medication.\n* Life expectancy \\\u003C6 months, current palliative\u002Fhospice care, or planned kidney transplant within ≤3 months.\n* Concurrent participation in another clinical trial that could interfere with the study interventions or outcomes.\n* Venography demonstrating significant venous stenosis involving the superior vena cava (SVC) or inferior vena cava (IVC).",{"count":118,"type":21},54,[120],"PHASE4","This randomized, single-center, PROBE trial evaluates whether adding low-dose apixaban (2.5 mg orally every 12 hours) to standard intraluminal heparin lock prolongs primary functional patency of tunneled hemodialysis catheters compared with standard heparin lock alone. Adult patients on hemodialysis with a recently implanted, functioning tunneled catheter (≥8 days) will be randomized 1:1 and followed up to 24 months (or until catheter loss). Primary outcome is time to first intervention for catheter dysfunction or definitive catheter loss. Secondary outcomes include primary-assisted and secondary patency, thrombotic dysfunction, rescue procedures, catheter-related infection, bleeding (ISTH), and mortality. Outcomes adjudication will be blinded.",[123,27,124],"Hemodialysis Access Failure","Hemodialysis Catheter",[126,127,128,129,130,131,132,133,134,135,136],"Hemodialysis","Tunneled central venous catheter","Catheter dysfunction","Catheter Failure","Catheter thrombosis","Apixaban","Heparin lock","End-stage kidney disease","Vascular access","Anticoagulation","PROBE trial","NOT_YET_RECRUITING","2026-02-12",{"date":140,"type":46},"2026-02-17",{"date":48,"type":21},{"date":143,"type":21},"2028-09-01",{"name":145,"class":53},"Hospital Civil de Guadalajara",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100522965","virtual-home-based-physical-pre-habilitation-in-kidney-transplant-candidates-100522965","NCT06089473","Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates","Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates: a Pilot RCT","Inclusion Criteria:\n\n* consecutive individuals with end stage kidney disease (ESKD) (aged ≥18 years), classified as pre-frail (1-2 points), frail (3-4 points) or very frail (5 points) on the Fried's frailty phenotype and who are accepted or in the process of being accepted to enter in the deceased or living donor KT waiting list of the McGill University Health Centre (MUHC), Centre Hospitalier de l'Université de Montreal (CHUM) or University of Alberta Hospital (UAH) for first-time transplantation or re-transplantation\n* English or French speakers\n* is technologically capable of connecting (either independently or through household members\u002Fnext-of-kin) with an online videoconferencing platform through an e-mail invitation (Patients who do not have access to internet will borrow a tablet with internet for the period of the study)\n\nExclusion Criteria:\n\n* Individuals who:\n* are classified as robust (0 points) on their Fried's frailty phenotype score\n* are participating in a structured exercise program (hospital-based or home-based or another trial)\n* are waiting for kidney-pancreas or kidney-liver transplant as those have much longer waiting time\n* are hospitalized for any reason during the assessment for eligibility\n* have a cPRA (calculated panel reactive antibodies) \\>95% and are on the highly sensitized exchange program and expected to have a prolonged waiting times on the waiting list\n* are expected to have a transplant before the end of the 12 week-intervention (e.g. individuals who will receive an organ from a living donor or are type A blood\n* have pre-existing or newly identified significant cognitive impairment\n* have pre-existing or newly identified cardiac, musculoskeletal, neuropathy or neurological condition that might affect their exercise performance or otherwise render rehabilitation participation unsafe",{"count":154,"type":21},30,[24],"The goal of this RCT is to address the feasibility of conducting a 12-week virtual pre-habilitation intervention, which includes exercise and education, in kidney transplant candidates. The intervention also includes a 5-month maintenance phase with independent home exercises (maximum of 8 months of intervention\u002Fended early if the participant undergoes a kidney transplant). The main questions it aims to answer are:\n\n* estimate the proportion of screened patients who meet eligibility criteria\n* estimate the proportion of eligible patients who consent to randomization\n* estimate the proportion of patients who adhere to the interventions\n* estimate follow-up completion rates\n* inform the calculation of sample size requirements for a full-scale RCT\n* assess the acceptability of the intervention by the participants.\n\nParticipants in the control group will receive usual outpatient care.",[27,158,159],"Frailty","Transplant;Failure,Kidney","2025-11-25",{"date":162,"type":46},"2025-12-03",{"date":164,"type":46},"2024-11-02",{"date":166,"type":21},"2027-02",{"name":168,"class":53},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",2,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":54},"100595564","path-03-paraguay-feasibility-study-100595564","NCT07034092","PATH-03 Paraguay Feasibility Study","Feasibility Study to Evaluate the Safety and Efficacy of the ePATH System for endoAVF Creation","Inclusion Criteria:\n\n1. Patients deemed eligible for creation of an AV fistula according to institutional or local guidelines and\u002For clinical judgement of the investigator\n2. Adults (age \\>18 years old)\n3. Non-reversible kidney failure requiring hemodialysis (this can include pre-dialysis patients)\n4. Target vein diameter of ≥2.0 mm\n5. Target artery diameter of ≥2.0 mm\n6. Both radial and ulnar artery flow to the hand, confirmed with Duplex Ultrasound and\u002For Allen's test (i.e. palmar arch)\n7. Able to provide informed consent\n8. Able to comply with follow-up visit assessment requirements\n9. Patient is free from clinically significant conditions or illnesses that might compromise the procedure or the AVF\n\nExclusion Criteria:\n\n1. Significant central venous stenosis or narrowing that exceeds 50% based on imaging\n2. Hypercoagulable state or known bleeding diathesis\n3. NHYA Class III or IV heart failure\n4. Estimated life-expectancy of \\\u003C1 year based on the physician's opinion\n5. Oedema of extremities\n6. Current diagnosis of carcinoma\n7. Pregnant or breastfeeding women\n8. Diagnosed or suspected skin disease at the access site\n9. Immunosuppression or otherwise immunocompromised patients\n10. Currently being treated with another investigational device or medication\n11. Allergy to contrast or other drugs associated with surgery, e.g., sedation agents, or to device materials\n12. Anatomy that prevents formation of AVF, e.g., misalignment of vessels or tortuosity\n13. Patient is unwilling to undergo 2nd stage procedure, e.g. endovascular prothesis placement or balloon dilatation, if required",{"count":178,"type":21},20,[24],"The goal of this study is to evaluate the safety and effectiveness of the ePATH system in the creation of an endovascular AVF (endoAVF) in patients who require or will soon require hemodialysis and are eligible for a fistula.",[27],[183,184],"fistula, AVF, endoAVF, hemodialysis, vascular access","endovascular AVF","2025-07-15",{"date":187,"type":46},"2025-07-17",{"date":189,"type":21},"2025-10",{"date":191,"type":21},"2026-10",{"name":193,"class":107},"Pathfinder Medical",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":63,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":54},"100577666","treat-assay-the-new-frontier-for-the-diagnosis-of-acute-rejection-in-kidney-transplantation-100577666","NCT06801262","TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation","Inclusion Criteria:\n\n* Inclusion criteria for subjects in group A Healthy adult subjects who will be selected from blood donors belonging to the Metropolitan Immunohematology and Transfusion Medicine Service. It should be noted that for subjects belonging to group A, informed consent is not required as the samples are provided in anonymous manner and completely unrelated to the patient.\n* Inclusion criteria for study patients group B\n\n  1. Subjects undergoing living or cadaveric kidney transplantation afferent to the O.U. of Nephrology, Dialysis and Renal Transplantation, St. Orsola Hospital, Pavilion 15.\n  2. Patients who intend to participate in the study.\n\nExclusion Criteria:\n\n* Exclusion criteria for subjects in group A None\n* Exclusion criteria for patients in study group B\n\n  1. Subjects under the age of 18 years.\n  2. Patients who are unable to make explicit their informed consent.",{"count":201,"type":21},150,"Kidney transplantation is the standard therapy for end-stage renal disease. Acute rejection (AR) or chronic rejection along with reactive donor immunity, which counteracts organ acceptance, are among the greatest medical challenges in transplantation.\n\nIn the posttransplantation setting, immunosuppressive drugs are administered to control or prevent immune reactions; however, the therapies have serious side effects. Retrospective studies have shown heterogeneous risk profiles with respect to post-transplant complications, such as AR or infection, suggesting the introduction of an individualized immunosuppressive regimen2,3,4. Biomarkers are needed for such individual therapies to discriminate between patients with different risk profiles.",[70,28,27],"2025-01-24",{"date":206,"type":46},"2025-01-30",{"date":208,"type":46},"2022-11-10",{"date":210,"type":21},"2026-05-01",{"name":212,"class":53},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]